I highlighted (Dec 2015) Teva’s SD-809 (deutetrabenazine) treatment for tardive dyskinesia. The disease causes uncontrollable movements in around 500,000 US patients. The second Phase III trial of the treatment produced statistically significant results.

http://www.tevapharm.com/news/teva_announces_positive_top_line_data_from_second_phase_iii_study_of_sd_809_in_tardive_dyskinesia_td_09_16.aspx